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ADCC = antibody-dependent cellular cytotoxicity; bsAbs = bispecific antibodies; CDC = complement-dependent cytotoxicity; EGFR = epidermal
growth factor receptor; FcgR = receptors for the Fc region of IgG antibodies; mAb = monoclonal antibody; NK = natural killer; scFv = single-chain
antibody variable region.
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Introduction
The Holy Grail of cancer therapy is to develop agents
capable of selectively destroying disseminated tumour
cells while sparing normal tissues. With this aim, major
efforts have been directed at harnessing the exquisite
specificity of the immune response. Hybridoma technology
has enabled the development of tumour selective mono-
clonal antibodies (mAbs) [1,2], and the past few years
have witnessed the approval by the Food and Drug
Administration of the first mAbs for the therapy of cancer:
Rituxan (anti-CD20) for non-Hodgkin’s lymphoma and
Herceptin [anti-(c-erbB-2/HER-2)] for metastatic breast
cancer. The purpose of this commentary is to summarise
known and recently reported properties of these mAbs
and consider whether recent findings might lead to more
effective therapies for cancer.
Targeted therapy for breast cancer
Although the earlier detection of breast cancer and
improvements in surgery and adjuvant therapy have
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Abstract
The first monoclonal antibodies (mAbs) approved for cancer therapy are now in Phase II and III trials,
but the critical mechanism(s) determining efficacy and response in patients are still largely undefined.
Both the direct antigen-binding (Fab) and constant (Fc) regions of mAbs can contribute to their
biological activity. However, Clynes et al (Nat Med 2000, 6:443) recently suggested that the latter (at
least in experimental models) might be the dominant component in vivo, triggering host responses to
destroy cancer cells. Those workers showed that in mice lacking ‘activation’ Fc receptors (FcgRI and
FcgRIII), anti-tumour effects of certain mAbs were significantly reduced. In contrast, mice deficient in
the ‘inhibitory’ receptor FcgRIIB responded with tumour growth inhibition and enhanced antibody-
dependent cellular cytotoxicity (ADCC). These observations suggest that mAbs might be engineered
for preferential binding to FcgRIII to maximise therapeutic benefit. However, further work is needed to
establish a definitive cause–effect relationship in experimental models that are more clinically relevant,
to determine whether human FcgR isoforms behave in a similar fashion, and to confirm that therapeutic
mAbs and host cells can adequately access solid tumour deposits to mediate effective ADCC in situ.
Finally, the ‘cost–benefit’ ratio of such modified macromolecules will need to be measured against
mini-mAb constructs, antisense oligonucleotides, peptidomimetics and emerging drugs capable of
inhibiting key tumour cell signalling pathways.
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improved survival rates, there are still around 15,000
deaths in the UK each year and 43,000 in the USA. This is
due primarily to the development of drug-resistant
metastatic disease. An increasing number of genetic
changes have been identified in breast and other cancers,
which are now being actively explored for targeted therapy
[3]. One of the most exciting new targets is the
c-erbB-2/HER-2/neu proto-oncogene, which is expressed
in 20–30% of breast and other carcinomas. Clinical
observations and laboratory experiments have demon-
strated convincingly that, together with the related epider-
mal growth factor receptor (EGFR), it is causally related to
maintenance of the malignant phenotype, functioning as a
critical signalling molecule in tumour cell proliferation,
motility, angiogenesis and metastasis [4]. The accessibility
of c-erbB-2 at the cell surface, low expression on normal
adult tissues and relatively homogeneous distribution
within ‘positive’ tumours and their metastases makes it an
ideal candidate for immunotherapeutic intervention [5].
Development of therapeutic mAbs and
determination of their mechanisms of action
Initially, attention focused on specificity and affinity, with
the selection of mAbs being based primarily on their ability
to inhibit tumour cell growth in vitro. Some mAbs are
extremely potent, with IC50 values (concentrations giving
half-maximal inhibition) in the nanomolar range, competing
well in this regard with low-molecular-mass tyrosine kinase
inhibitors. Once good target selectivity had been
achieved, mAbs were chemically or genetically modified to
decrease their immunogenicity in patients and to improve
their physicochemical properties. Antibodies are struc-
turally complex macromolecules with multiple functions.
Some, but by no means all, of their activities depend on
the complementarity-determining regions within the spe-
cific antigen-binding site. When directed against signalling
molecules such as CD20, c-erbB-2/HER-2 and EGFR,
mAbs can exert either agonistic or antagonistic (potentially
therapeutic) effects. Simply stated, antagonistic mAbs can
be shown to ‘remove’ and/or to ‘switch off’ their target
antigen, resulting in anti-proliferative effects. For example,
4D5 (the murine mAb from which Herceptin was derived)
partly blocks heregulin-induced receptor phosphorylation
and transphosphorylation. However, the major effect of
these mAbs seems to be receptor downmodulation,
potentially preventing heterodimerisation and activation of
other HER family members and downstream signalling [6].
Cell cycle progression is inhibited and cells are arrested in
G0/G1; they can subsequently undergo terminal differenti-
ation or apoptosis, depending on the cell type.
Some antagonistic mAbs preferentially enhance ubiquiti-
nation and degradation of their target [7] and yet others
(exemplified by certain anti-EGFR mAbs [8]) do not signifi-
cantly downregulate receptor expression but effectively
compete with the cognate growth factors for receptor
binding and activation. With Rituxan, it has been shown
that the target antigen CD20 is not downregulated, but
the mAb induces apoptosis and sensitises cells to the
effects of conventional therapy [9]. Thus, even considering
the direct effect of mAbs, it is clear that there are a multi-
plicity of possible responses determined by the properties
of the antigen, the antibody, and the cellular context.
Engineering mAbs for improved clinical utility
The major problems of mAb therapy are related to the
immunogenicity of rodent proteins and the relatively poor
penetration of intact immunoglobulin molecules into solid
tumours. The former has been addressed by making
chimeric mAbs (human constant region plus mouse vari-
able region) or ‘humanised’ mAbs in which the human
framework Ig contains only rodent sequences encoding
the three complementarity-determining regions, as in Her-
ceptin. Another method of reducing immunogenicity and
assisting penetration into solid tumours is to remove the
constant (Fc) region and to prepare monomeric or dimeric
antibody fragments such as Fab, F(ab¢)2 and single-chain
antibody variable region (scFv). However, it was noted that
some mAbs were more active in vivo than in vitro, and this
benefit was lost if the Fc portion was removed. Although
this is partly explained by the lower affinity and/or shorter
half-life of these molecules, results with chemically and
genetically modified Fc regions led to an appreciation of
the possible contribution of indirect host effects mediated
by interactions between IgG Fc and receptors for the Fc
region (FcgR) [10].
The recent paper by Clynes et al [11] highlights further
subtleties relating to mAb interaction with specific FcR
subtypes; the authors now suggest that this is a dominant
component of the activity of Herceptin and similar mAbs.
The experiments described, although elegant, leave
several unanswered questions about the interpretation of
the data and their clinical relevance. We need to consider
whether the differential effects of mAb therapy observed in
the genetically modified mice are linked directly to their
FcR status, and if so whether similar effects are likely to
occur in humans, and finally whether antibody-dependent
cellular cytotoxicity (ADCC) is a feasible goal for effective
therapy in cancer patients.
The contribution of host effector mechanisms
to mAb activity in vivo
FcgRs are the key link between humoral and cellular
immune responses. They are important in immune regula-
tion and mediate ADCC, endocytosis, phagocytosis, the
release of inflammatory cytokines and antigen presenta-
tion. FcgR comprise three classes: FcgRI (CD64) FcgRII
(CD32) and FcgRIII (CD16). Each class also contains iso-
forms that exhibit different binding affinities for IgG sub-
classes, and further complexities arise from their
differential expression on host cell populations and theBreast Cancer Research    Vol 3 No 2 Eccles
presence of variant alleles in the low-affinity II and III
receptor subtypes [12]. FcgRI and III are multimeric ‘acti-
vation’ receptors, containing both a ligand-binding subunit
and a signalling subunit, the immunoreceptor tyrosine-
based activation (ITAM) motif, but if co-ligated to the
monomeric FcgRIIb (which contains an inhibitory ITIM
motif), responses are downregulated.
Herceptin contains a human g1 Fc and interacts primarily
with FcRgIII on natural killer (NK) cells and monocytes. The
binding of free mAb is quite weak, but once bound with high
affinity to c-erbB-2 on the tumour cell surface, it mediates
effective ADCC in vitro [6]. Clynes et al [11] now show that
Herceptin (and Rituxan) also bind FcgRIIB (present on
monocytes and macrophages, but not NK cells) and that if
this interaction is prevented, ADCC is enhanced. They have
also shown, with three different experimental systems
(including therapy of breast carcinoma xenografts with Her-
ceptin) that the efficacy of mAbs in vivo was, first, reduced if
the Fc portion was deleted; second, reduced in mice defi-
cient in FcgRI and RIII, and third, enhanced in mice deficient
in FcgRIIB. However, first, it should be noted that the breast
carcinoma (and lymphoma) were grown ectopically (subcu-
taneously) and in all cases therapy was commenced on day
0, maximising the opportunity for the administered antibody
(or activated host cells) to exert therapeutic effects.
Second, the behaviour of mAbs in congenitally athymic
mice is not equivalent to that in immunocompetent hosts
[13]. In the former, the effector function of NK cells and
monocytes is enhanced in compensation for a lack of T cell
function, and circulating Ig levels are abnormally low.
Although a third model used melanoma cells injected intra-
venously into inbred C57/bl mice, these are known to be a
‘high responder’ strain immunologically. On balance, it
would therefore be premature to use the current data to
predict responses in heterogeneous, generally aged, often
immunodeficient, human cancer patients in which the clini-
cal problem is established, disseminated disease.
There are also several extra studies that could strengthen
the conclusion that FcR status is causally related to mAb
therapeutic efficacy in vivo. Although it was shown that
the tumours grew similarly in the nu/nu hosts and those
crossed with different FcgR-deficient strains, it would be
important to show the following: (1) that the HER2 expres-
sion and kinase activity of the transplanted tumours were
equivalent in all hosts, (2) that tumours with different
expression levels responded as predicted, and (3) that the
tumour response to direct-acting agents was equivalent —
these could be HER-2 tyrosine kinase inhibitors, non-
ADCC-mediating mAbs, drug or radioisotope conjugates.
These studies should exclude any epigenetic modifiers of
response that could inadvertently have been introduced by
selective breeding. For example, it has been shown that
HER-2 expression (and Herceptin) can alter the sensitivity
of tumour cells to cytokines such as tumour necrosis
factor-a, and it might be that the different hosts vary in
their endogenous (or mAb-activatable) cytokine profiles.
With Rituxan, which is a chimeric mAb comprising human
g1 Fc plus mouse anti-CD20 Fab regions, both ADCC
and complement-dependent cytotoxicity (CDC) have been
demonstrated in vitro, although the main determinants of
its clinical efficacy have not been defined. Indeed, it has
never been formally proved that ADCC operates in
patients, and some mAbs that perform well in ADCC
assays fail in clinical trials. Clynes’s data (confirming
reports by Funakoshi [14]) show a significant FcgRIII-
dependent host component of anti-CD20 (Rituxan) in the
response of xenografts in athymic mice. However, in B
lymphomas in immunocompetent animals, Tutt et al [15]
found that in most cases crosslinking and inhibitory sig-
nalling by mAbs directed against surface immunoglobulin
idiotype, CD19 and CD40 were more important than the
recruitment of host effectors.
Thus, although host mechanisms clearly can contribute to
mAb-induced therapeutic responses, their importance
varies in different situations. Activity in vitro (either direct
or mediated via ADCC or CDC) does not seem to predict
activity in vivo, so we must understand that patients’ indi-
vidual responses are the sum of multiple factors including
expression of the target antigen (and other signalling mol-
ecules that might compensate if the former is inactivated),
levels of circulating Ig or immune complexes and the func-
tional status of their effector cells.
How does the manipulation of FcR
interactions compare with other strategies?
Host immune responses can also be induced by the use
of bispecific antibodies (bsAbs) in which one Fab arm
recognises tumour antigen and the other engages epi-
topes on T cells (CD3) [16], or specific FcgR [17]. These
constructs, unlike Herceptin and Rituxan, are monomeric,
which might be a disadvantage (because of their lower
affinity), but a new class of bsAbs has been designed that
recognises tumour cell EpCAM antigen and CD3, and has
an Fc composed of a mouse g2a heavy chain and a rat
g2b heavy chain: like human g1, two very potent activators
of FcR. mAb BiUII has been shown to activate T cells
expressing CD3, monocytes and macrophages expressing
FcgRIII, NK cells expressing RI, but not B cells expressing
RII/CD32 [18]. Although clinical use might be limited by
human anti-mouse and anti-rat (HAMA and HARA)
responses, these heterologous Fc regions proved more
active than either homologous Fc and showed the advan-
tage of recruitment of multiple classes of host effectors. In
contrast, bsAbs recognising HER2 and FcgRIII (for
example 2B1) have had limited clinical utility owing to toxi-
city, although bispecific scFv might overcome some of the
problems [19]. The relative merits of these different con-
structs remain to be fully explored clinically [20].Do the recent observations by Clynes et al have implica-
tions for the future design of therapeutic mAbs, and how
will these measure up to other agents? Theoretically, if the
Fc region could be engineered to give selective binding to
FcgRIII relative to FcgRIIB, activation of host effector cells
could be maximised. This group found that a single amino
acid change at residue 265 of the CH2 domain of murine
mAb 4D5 was sufficient to reduce its binding to FcR,
abrogate ADCC activity and compromise efficacy in vivo.
However, binding to both the activation RIII and the
inhibitory RIIb receptors was decreased, with no evidence
of selectivity. The specificity of binding of Ig isotypes to
different FcR isoforms and allotypes is complex, with both
CH2 regions 234–237 and the CH2/CH3 interface being
implicated [21]. In addition, there is a high degree of
homology between the ectodomains of many receptors,
suggesting very similar binding profiles.
Careful and comprehensive analysis of the binding specifici-
ties of mutated mAbs to human effector cells, ideally har-
vested from cancer patients, would therefore be essential to
predict the net effect of changing FcR interactions. FcgRIIB
expressed on follicular dendritic cells in germinal centres
has also recently been shown to be important for the regula-
tion of B cell recall responses, and it is possible that this
could contribute to host anti-tumour responses in patients
[22]. A further consideration is the expression of the FcgR
variant alleles in control and disease populations, which
might also influence response to therapeutic mAbs [23,24].
Many trials with Herceptin are under way, but as previ-
ously stated there is as yet no hard evidence that ADCC is
contributing to therapeutic response. It would seem
logical to explore this further before steps are taken to
generate FcgRIII-selective mAbs as proposed by Clynes et
al, because if patients are unable to mobilise effector cells
to sites of metastasis, the strategy will fail. The CAMPATH
1 mAb (which is a rat g2b isotype directed against CD52)
is a powerful inducer of CDC and ADCC against antigen-
positive lymphoid malignancies. However, although it
depleted target cells effectively from blood, spleen and
bone marrow, it was much less effective against solid
tumour deposits [25].
Increasingly, emphasis is being placed on pharmaco-
dynamic endpoints and surrogate markers of response in
trials of novel therapies, and mAbs should be no excep-
tion. It should be possible to check that patients have ade-
quate levels of NK cells and monocytes before therapy
and that these are responsive in ADCC assays. Once
therapy is under way, trials could be designed (similar to
those with bsAbs) to assess immunological function, for
example evidence of CD16-positive host cell recruitment
into accessible tumour deposits and circulating cytokine
levels. In addition, to examine whether other mechanisms
are operating, it would be worth checking for the induction
of idiotypic antibody cascades and cell-mediated
responses to HER-2.
Finally, the efficacy and cost of novel engineered mAbs
must be critically compared with new low-molecular-mass
agents that inhibit c-erbB-2 and EGFR tyrosine kinases.
These include a 1.5 kDa exocyclic anti-HER2/neu peptide
mimic [26] and also orally active agents with cellular
inhibitory activity in the nanomolar range [27]. Whatever
the final outcome, the use of increasingly sophisticated
genetically engineered antibodies, cells and animal
models will lead to a much greater understanding of
tumour–host interactions and how they can best be
manipulated for therapeutic benefit. Even when tumours
are preselected to be antigen positive, only a minority of
patients respond to mAb therapy. If Clynes et al are
correct, this might be due to the ability of their NK cells
and monocytes to become ‘triggered’ by the therapeutic
mAb to kill tumour cells. These are exciting times and
effective targeted therapy for cancers is close to being a
reality. Whether the ‘magic bullets’ will be mAbs, their
derivatives or synthetic drugs remains to be seen.
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